Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05807659
Other study ID # Fra-Bu 1.0
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date March 16, 2023
Est. completion date December 31, 2025

Study information

Verified date March 2023
Source Sichuan University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this single-arm phase II study is to test in patients with non-remission myeloid malignancies undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT). The main question it aims to answer are: - The safety and efficacy of fractionated busulfan Combined With Chidamide/Fludarabine/Cytarabine(ChiFAB) conditioning regimen in increasing the overall survival rate in patients with non-remission myeloid malignancies after allo-HSCT. - The efficacy of fractionated busulfan conditioning regimen in reducing the recurrence rate in patients with non-remission myeloid malignancies after allo-HSCT. Participants will receive fractionated busulfan-based ChiFAB conditioning regimen (busulfan 3.2mg/kg d-13, -12, 1.6mg/kg d-6~-3, fludarabine 35mg/m2 d-6~-2, cytarabine 1g/m2,d-6~-2, chidamide 30mg d-13,-10,-6,-3) before allo-HSCT.


Recruitment information / eligibility

Status Recruiting
Enrollment 18
Est. completion date December 31, 2025
Est. primary completion date August 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Age = 18 years old and = 65 years old when signing the Informed Consent Form (ICF); 2. KPS score > 60 or ECOG score 0-2; 3. The expected survival period > 3 months; 4. Those who did not achieve complete remission after 2 or more chemotherapy regimens. The proportion of blasts on bone marrow smears before transplantation was =5%. 5. Those who have no central nervous system involvement or serious functional damage to important organs of the body; 6. Fully understand and be informed of this study and sign the ICF; willing to follow and have the ability to complete all test procedures; Exclusion Criteria: 1. Serious basic diseases of important organs: such as myocardial infarction, chronic cardiac insufficiency, decompensated hepatic insufficiency, renal function, gastrointestinal insufficiency, etc.; 2. Uncontrolled active infection (including bacterial, fungal, or viral infection), and drug treatment is ineffective; 3. Participating in other clinical studies, or planning to start treatment in this study and less than 4 weeks before the end of treatment in the previous clinical study; 4. Combined with other malignant tumors and require treatment; 5. Pregnant or lactating females; 6. Patients with known history of human immunodeficiency virus (HIV) virus infection and/or acquired immunodeficiency syndrome; 7. Patients with active chronic hepatitis B or active hepatitis C; 8. History of prolonged QT syndrome; 9. Patients considered by other researchers to be unsuitable for this study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
fractionated busulfan-based conditioning regimen
Drug: Chidamide 30 mg oral twice weekly for 2 weeks Drug: Fludarabine 35 mg/m2 intravenously daily for 5 days in the 2nd week Drug: Cytarabine 1 g/m2 intravenously for 5 days in the 2nd week Drug: Busulfan 3.2 mg/kg intravenously daily for 2 days in the 1st week, 1.6 mg/kg intravenously daily for 4 days in the 2nd week Procedure/Surgery: allogeneic hematopoietic stem cell transplantation

Locations

Country Name City State
China West China Hospital, Sichuan University Chendu Sichuan

Sponsors (1)

Lead Sponsor Collaborator
Sichuan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival (OS) Overall survival of this group of patients at the end of 2 year 2 years
Secondary Non-relapse mortality (NRM) Non-relapse mortality of this group of patients at the end of 6 months 6 months
Secondary Relapse rate Relapse rate of this group of patients at the end of 2 year 2 years
Secondary Cumulative incidence of acute graft versus host disease (aGVHD) Cumulative incidence of acute graft versus host disease (aGVHD) of this group of patients at day+100 Day +100
Secondary Cumulative incidence of chronic graft versus host disease (cGVHD) Cumulative incidence of chronic graft versus host disease (cGVHD) of this group of patients at the end of 2 year 2 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06383572 - Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies Phase 1/Phase 2
Completed NCT01731951 - Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis Phase 2
Recruiting NCT02958384 - A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies Phase 1/Phase 2
Recruiting NCT02958397 - A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies Phase 1/Phase 2
Recruiting NCT05775406 - Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors Phase 1
Active, not recruiting NCT02452697 - Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT Phase 2
Completed NCT04778410 - Study of Magrolimab Combinations in Participants With Myeloid Malignancies Phase 2
Terminated NCT01366612 - PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation Phase 3
Completed NCT03270748 - Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies Phase 2
Recruiting NCT05115630 - Off-the-shelf NK Cells + SCT for Myeloid Malignancies Phase 1/Phase 2
Recruiting NCT05796570 - A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies Phase 2